Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

One MRI scan to rule them all? new study tests organ health in diabetes

NCT ID NCT04137705

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a single, standardized MRI scan can reliably measure body composition and the health of multiple organs—like the liver, pancreas, heart, and kidneys—in people with type 2 diabetes and healthy volunteers. 43 participants were scanned twice on the same machine and on different machines to check how repeatable the measurements were. The goal was to see if this approach could be a useful tool for future research or clinical care, not to treat the disease itself.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this MRI method could help doctors better understand how type 2 diabetes affects multiple organs, potentially leading to earlier detection or monitoring.
What could go wrong
This is a small, early-stage study focused on measuring reproducibility, not on treating or curing diabetes. The results may not apply to all patients or scanners.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

43 people

The number who actually took part.

Started

Nov 2019

Finished

Nov 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult volunteers, including healthy volunteers and individuals with Type 2 Diabetes (T2D).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any person over 18 years of age. * Participant is willing and able to give informed consent for participation in the investigation. * EITHER: Participant has Type 2 Diabetes OR: Person is a healthy volunteer Exclusion Criteria: * The participant may not enter the investigation if they have any contraindication to magnetic resonance imaging (incl. pregnancy, extensive tattoos, pacemaker, shrapnel injury, severe claustrophobia). * Any other cause, including a significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the investigation, or may influence the result of the investigation, or the participant's ability to participate in the investigation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beaver House

    Oxford, OX1 2EH, United Kingdom

  • Gemini One

    Oxford, OX4 2LL, United Kingdom

  • Oxford Centre for Magnetic Resonance

    Oxford, OX3 9DU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.